Analysis of cell-mediated immune responses in support of dengue vaccine development efforts

Vaccine

Volumn 33, Issue 50, 2015, Pages 7083-7090

  Rothman, Alan L ^a   Currier, Jeffrey R ^b   Friberg, Heather L ^b   Mathew, Anuja ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Cell mediated immunity; Dengue; Vaccine

Indexed keywords

DENGUE VACCINE; EPITOPE;

ARTICLE; CELLULAR IMMUNITY; CROSS REACTION; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; HUMAN; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY INFECTION; T LYMPHOCYTE SUBPOPULATION; VACCINATION; ANIMAL; IMMUNOLOGY;

ANIMALS; DENGUE; DENGUE VACCINES; HUMANS; IMMUNITY, CELLULAR;

EID: 84951320391     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.104     Document Type: Article

References (94)

1. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
2. Thomas S.J., Hombach J., Barrett A. Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. Vaccine 2009, 27:355-368.
3. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
4. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.
5. Kara E.E., Comerford I., Fenix K.A., Bastow C.R., Gregor C.E., McKenzie D.R., et al. Tailored immune responses: novel effector helper T cell subsets in protective immunity. PLoS Pathog 2014, 10:e1003905.
6. Tripathi S.K., Lahesmaa R. Transcriptional and epigenetic regulation of T-helper lineage specification. Immunol Rev 2014, 261:62-83.
7. Cheroutre H., Husain M.M. CD4 CTL: living up to the challenge. Semin Immunol 2013, 25:273-281.
8. Peck A., Mellins E.D. Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 2010, 129:147-153.
9. Restifo N.P., Gattinoni L. Lineage relationship of effector and memory T cells. Curr Opin Immunol 2013, 25:556-563.
10. Gasper D.J., Tejera M.M., Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol 2014, 34:121-146.
11. Chang J.T., Wherry E.J., Goldrath A.W. Molecular regulation of effector and memory T cell differentiation. Nat Immunol 2014, 15:1104-1115.
12. Thakur A., Pedersen L.E., Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012, 30:4907-4920.
13. Finak G., Jiang W., Krouse K., Wei C., Sanz I., Phippard D., et al. High-throughput flow cytometry data normalization for clinical trials. Cytometry A 2014, 85:277-286.
14. Saade F., Gorski S.A., Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. Expert Rev Vaccines 2012, 11:1459-1470.
15. Dubey S., Clair J., Fu T.M., Guan L., Long R., Mogg R., et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007, 45:20-27.
16. Horton H., Thomas E.P., Stucky J.A., Frank I., Moodie Z., Huang Y., et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007, 323:39-54.
17. Bjornson Z.B., Nolan G.P., Fantl W.J. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol 2013, 25:484-494.
18. Chattopadhyay P.K., Roederer M. A mine is a terrible thing to waste: high content, single cell technologies for comprehensive immune analysis. Am J Transpl 2015, 15:1155-1161.
19. Roederer M. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry A 2011, 79:95-101.
20. Plessy C., Desbois L., Fujii T., Carninci P. Population transcriptomics with single-cell resolution: a new field made possible by microfluidics: a technology for high throughput transcript counting and data-driven definition of cell types. Bioessays 2013, 35:131-140.
21. Trautmann L., Sekaly R.P. Solving vaccine mysteries: a systems biology perspective. Nat Immunol 2011, 12:729-731.
22. Manrique A., Adams E., Barouch D.H., Fast P., Graham B.S., Kim J.H., et al. The immune space: a concept and template for rationalizing vaccine development. AIDS Res Hum Retroviruses 2014, 30:1017-1022.
23. Todd C.A., Sanchez A.M., Garcia A., Denny T.N., Sarzotti-Kelsoe M. Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL). J Immunol Methods 2014, 409:91-98.
24. Sanchez A.M., Denny T.N., O'Gorman M. Introduction to a Special Issue of the Journal of Immunological Methods: building global resource programs to support HIV/AIDS clinical trial studies. J Immunol Methods 2014, 409:1-5.
25. Staats J.S., Enzor J.H., Sanchez A.M., Rountree W., Chan C., Jaimes M., et al. Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays. J Immunol Methods 2014, 409:44-53.
26. Rountree W., Vandergrift N., Bainbridge J., Sanchez A.M., Denny T.N. Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry. J Immunol Methods 2014, 409:72-81.
27. Sambor A., Garcia A., Berrong M., Pickeral J., Brown S., Rountree W., et al. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. J Immunol Methods 2014, 409:107-116.
28. Sanchez A.M., DeMarco C.T., Hora B., Keinonen S., Chen Y., Brinkley C., et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J Immunol Methods 2014, 409:117-130.
29. Garcia A., Keinonen S., Sanchez A.M., Ferrari G., Denny T.N., Moody M.A. Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. J Immunol Methods 2014, 409:99-106.
30. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012, 37:1-2.
31. Janetzki S., Britten C.M., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., et al. MIATA-minimal information about T cell assays. Immunity 2009, 31:527-528.
32. Kurane I., Ennis F.A. Immunity and immunopathology in dengue virus infections. Semin Immunol 1992, 4:121-127.
33. Rothman A.L. Immunology and immunopathogenesis of dengue disease. Adv Virus Res 2003, 60:397-419.
34. Simmons C.P., Dong T., Chau N.V., Dung N.T., Chau T.N., Thao le T.T., et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005, 79:5665-5675.
35. Mangada M.M., Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 2005, 175:2676-2683.
36. Bashyam H.S., Green S., Rothman A.L. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006, 176:2817-2824.
37. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal. J Immunol 2006, 176:3821-3829.
38. de la C.S.B., Garcia G., Perez A.B., Morier L., Alvarez M., Kouri G., et al. Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol 2006, 19:662-668.
39. Appanna R., Huat T.L., See L.L., Tan P.L., Vadivelu J., Devi S. Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol 2007, 14:969-977.
40. Imrie A., Meeks J., Gurary A., Sukhbataar M., Kitsutani P., Effler P., et al. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 2007, 81:10081-10091.
41. Dong T., Moran E., Vinh Chau N., Simmons C., Luhn K., Peng Y., et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS ONE 2007, 2:e1192.
42. Wen J.S., Jiang L.F., Zhou J.M., Yan H.J., Fang D.Y. Computational prediction and identification of dengue virus-specific CD4(+) T-cell epitopes. Virus Res 2008, 132:42-48.
43. Moran E., Simmons C., Vinh Chau N., Luhn K., Wills B., Dung N.P., et al. Preservation of a critical epitope core region is associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-specific CD4+ T cell clone. Eur J Immunol 2008, 38:1050-1057.
44. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26:5712-5721.
45. Wen J., Duan Z., Jiang L. Identification of a dengue virus-specific HLA-A*0201-restricted CD8+ T cell epitope. J Med Virol 2010, 82:642-648.
46. Dung N.T., Duyen H.T., Thuy N.T., Ngoc T.V., Chau N.V., Hien T.T., et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol 2010, 184:7281-7287.
47. Duangchinda T., Dejnirattisai W., Vasanawathana S., Limpitikul W., Tangthawornchaikul N., Malasit P., et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 2010, 107:16922-16927.
48. Friberg H., Burns L., Woda M., Kalayanarooj S., Endy T.P., Stephens H.A., et al. Memory CD8(+) T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 2011, 89:122-129.
49. Sun P., Beckett C., Danko J., Burgess T., Liang Z., Kochel T., et al. A dendritic cell-based assay for measuring memory T cells specific to dengue envelope proteins in human peripheral blood. J Virol Methods 2011, 173:175-181.
50. Hatch S., Endy T.P., Thomas S., Mathew A., Potts J., Pazoles P., et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011, 203:1282-1291.
51. Friberg H., Bashyam H., Toyosaki-Maeda T., Potts J.A., Greenough T., Kalayanarooj S., et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep 2011, 1:51.
52. Testa J.S., Shetty V., Sinnathamby G., Nickens Z., Hafner J., Kamal S., et al. Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response. J Infect Dis 2012, 205:647-655.
53. Malavige G.N., Huang L.C., Salimi M., Gomes L., Jayaratne S.D., Ogg G.S. Cellular and cytokine correlates of severe dengue infection. PLoS ONE 2012, 7:e50387.
54. Malavige G.N., McGowan S., Atukorale V., Salimi M., Peelawatta M., Fernando N., et al. Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses. Clin Exp Immunol 2012, 168:215-223.
55. Lindow J.C., Borochoff-Porte N., Durbin A.P., Whitehead S.S., Fimlaid K.A., Bunn J.Y., et al. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Neglected Trop Dis 2012, 6:e1742.
56. Rivino L., Kumaran E.A., Jovanovic V., Nadua K., Teo E.W., Pang S.W., et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013, 87:2693-2706.
57. Rivino L., Tan A.T., Chia A., Kumaran E.A., Grotenbreg G.M., MacAry P.A., et al. Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity. J Immunol 2013, 191:4010-4019.
58. Chang C.X., Tan A.T., Or M.Y., Toh K.Y., Lim P.Y., Chia A.S., et al. Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol 2013, 43:1109-1120.
59. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 2013, 110:E2046-E2053.
60. Talarico L.B., Bugna J., Wimmenauer V., Espinoza M.A., Quipildor M.O., Hijano D.R., et al. T helper type 2 bias and type 17 suppression in primary dengue virus infection in infants and young children. Trans R Soc Trop Med Hyg 2013, 107:411-419.
61. Harenberg A., Begue S., Mamessier A., Gimenez-Fourage S., Ching Seah C., Wei Liang A., et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother 2013, 9:2317-2325.
62. Malavige G.N., Jeewandara C., Alles K.M., Salimi M., Gomes L., Kamaladasa A., et al. Suppression of virus specific immune responses by IL-10 in acute dengue infection. PLoS Neglected Trop Dis 2013, 7:e2409.
63. Nascimento E.J., Mailliard R.B., Khan A.M., Sidney J., Sette A., Guzman N., et al. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Neglected Trop Dis 2013, 7:e2497.
64. Nguyen T.H., Nguyen T.H., Vu T.T., Farrar J., Hoang T.L., Dong T.H., et al. Corticosteroids for dengue - why don't they work?. PLoS Neglected Trop Dis 2013, 7:e2592.
65. Townsley E., Woda M., Thomas S.J., Kalayanarooj S., Gibbons R.V., Nisalak A., et al. Distinct activation phenotype of a highly conserved novel HLA-B57-restricted epitope during dengue virus infection. Immunology 2014, 141:27-38.
66. Piazza P., Campbell D., Marques E., Hildebrand W.H., Buchli R., Mailliard R., et al. Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol 2014, 177:696-702.
67. Comber J.D., Karabudak A., Huang X., Piazza P.A., Marques E.T., Philip R. Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin Immunother 2014, 10:3531-3543.
68. Duan Z., Guo J., Huang X., Liu H., Chen X., Jiang M., et al. Identification of cytotoxic T lymphocyte epitopes in dengue virus serotype 1. J Med Virol 2015, 87:1077-1089.
69. Weiskopf D., Angelo M.A., Bangs D.J., Sidney J., Paul S., Peters B., et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2015, 89:120-128.
70. Weiskopf D., Bangs D.J., Sidney J., Kolla R.V., De Silva A.D., de Silva A.M., et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci USA 2015, 112:E4256-E4263.
71. Weiskopf D., Cerpas C., Angelo M.A., Bangs D.J., Sidney J., Paul S., et al. Human CD8+ T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J Infect Dis 2015.
72. Rivino L., Kumaran E.A., Thein T.L., Too C.T., Gan V.C., Hanson B.J., et al. Virus-specific T lymphocytes home to the skin during natural dengue infection. Sci Transl Med 2015, 7:278ra35.
73. Jeewandara C., Adikari T.N., Gomes L., Fernando S., Fernando R.H., Perera M.K., et al. Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infection. PLoS Neglected Trop Dis 2015, 9:e0003673.
74. Chu H., George S.L., Stinchcomb D.T., Osorio J.E., Partidos C.D. CD8+ T-cell responses in flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J Infect Dis 2015.
75. Duan Z.L., Liu H.F., Huang X., Wang S.N., Yang J.L., Chen X.Y., et al. Identification of conserved and HLA-A*2402-restricted epitopes in dengue virus serotype 2. Virus Res 2015, 196:5-12.
76. Weiskopf D., Yauch L.E., Angelo M.A., John D.V., Greenbaum J.A., Sidney J., et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J Immunol 2011, 187:4268-4279.
77. Weiskopf D., Angelo M.A., Sidney J., Peters B., Shresta S., Sette A. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J Virol 2014, 88:11383-11394.
78. Jaiswal S., Pearson T., Friberg H., Shultz L.D., Greiner D.L., Rothman A.L., et al. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice. PLoS ONE 2009, 4:e7251.
79. Jaiswal S., Pazoles P., Woda M., Shultz L.D., Greiner D.L., Brehm M.A., et al. Enhanced humoral and HLA-A2-restricted dengue virus-specific T-cell responses in humanized BLT NSG mice. Immunology 2012, 136:334-343.
80. Vaughan K., Greenbaum J., Blythe M., Peters B., Sette A. Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol 2010, 23:259-284.
81. Mongkolsapaya J., Dejnirattisai W., Xu X., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9:921-927.
82. Rothman A.L. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010, 338:83-98.
83. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
84. Gil L., Bernardo L., Pavon A., Izquierdo A., Valdes I., Lazo L., et al. Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol 2012, 93:1204-1214.
85. Yauch L.E., Prestwood T.R., May M.M., Morar M.M., Zellweger R.M., Peters B., et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010, 185:5405-5416.
86. Mangada M.M., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H., et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 2002, 185:1697-1703.
87. Gunther V.J., Putnak R., Eckels K.H., Mammen M.P., Scherer J.M., Lyons A., et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 2011, 29:3895-3904.
88. Araki K., Turner A.P., Shaffer V.O., Gangappa S., Keller S.A., Bachmann M.F., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
89. Turner A.P., Shaffer V.O., Araki K., Martens C., Turner P.L., Gangappa S., et al. Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transpl 2011, 11:613-618.
90. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
91. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
92. Tan Y., Tamayo P., Nakaya H., Pulendran B., Mesirov J.P., Haining W.N. Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. Eur J Immunol 2014, 44:285-295.
93. Hadinegoro S.R., Arredondo-Garcia J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015.
94. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.